Metformin is one of the most prescribed medicines in the world — an oral drug used for type 2 diabetes for more than six decades, with one of the most established safety profiles in clinical pharmacology. In recent years it has become something quite different in research circles: the subject of the largest clinical trial ever designed specifically to test whether a drug can slow the biological ageing process in healthy adults.
This guide explains what metformin does, what the current evidence looks like as of June 2026, where the landmark TAME trial stands, and whether any of this is relevant to a healthy person in Australia thinking about anti-ageing. See our anti-aging skin care guide for the broader picture beyond systemic approaches like this one.
What Is Metformin? Key Facts
| Factor | Detail |
| Drug class | Biguanide |
| Primary approved use | Type 2 diabetes mellitus (blood glucose lowering) |
| How it works (primary) | Reduces hepatic glucose production; improves insulin sensitivity |
| Australian regulatory status | Prescription-only (Schedule 4); PBS-listed for type 2 diabetes |
| Availability | Available at Australian pharmacies with a valid prescription |
| Safety record | 60+ years of clinical use; very well-established safety profile |
| Common brand names | Metformin, Glucophage, Diaformin, Diabex |
Why Metformin Is Being Studied for Ageing
Metformin’s anti-ageing hypothesis emerged from observational data: diabetic patients taking metformin were found to have lower rates of cardiovascular disease, certain cancers, and all-cause mortality compared to both diabetic patients not taking it and — in some analyses — even healthy non-diabetic populations. This was striking enough to motivate formal clinical investigation.
At the molecular level, metformin activates AMPK (adenosine monophosphate-activated protein kinase) — a cellular energy sensor involved in multiple processes connected to ageing biology:
| Mechanism | What It Does | Ageing Relevance |
| AMPK activation | Acts as cellular “low fuel” signal | Triggers cell repair processes |
| mTOR inhibition (indirect) | Reduces cell growth signalling | mTOR overactivation linked to accelerated ageing |
| Autophagy stimulation | Cellular cleanup of damaged components | Reduced autophagy is a hallmark of ageing |
| Mitochondrial function | Modestly reduces mitochondrial electron transport | Reduces reactive oxygen species production |
| Anti-inflammatory effects | Reduces NF-κB pathway activation | Chronic inflammation drives “inflammageing” |
The TAME Trial: What It Is and Where It Stands in 2026
The Targeting Ageing with Metformin (TAME) trial is the most significant clinical study in ageing medicine currently underway. Key facts:
| Detail | Information |
| Sponsor | National Institute on Aging (NIA), USA |
| Coordinating centre | Albert Einstein College of Medicine |
| Trial registration | NCT03451006 |
| Participants | ~3,000 adults aged 65–79, without diabetes |
| Design | Randomised, double-blind, placebo-controlled |
| Primary outcome | Composite of: time to first occurrence of cardiovascular disease, cancer, dementia, physical disability, or death |
| Why it matters | First FDA-approved trial specifically targeting the ageing process itself (not a specific disease) |
| Enrollment status | Completed, early 2026 |
| Results expected | No earlier than 2028 |
| Current status | Ongoing — no efficacy data published as of June 2026 |
What this means right now: The most rigorous evidence about whether metformin genuinely slows ageing in healthy adults does not yet exist. We are waiting for it. The TAME trial will provide that answer, but not before 2028 at the earliest.
What the Existing Evidence Shows
Observational Data in Humans
Multiple large cohort studies have found metformin users with type 2 diabetes have lower rates of specific age-related diseases. A notable analysis from the UK Clinical Practice Research Datalink found diabetic patients on metformin had lower all-cause mortality than matched non-diabetic controls not on any medication — a finding that, if replicated in a controlled trial, would be remarkable.
Limitation of observational data: Confounding is substantial. People prescribed metformin and adhering to it are also more likely to engage with healthcare, have more regular medical monitoring, and make other healthy lifestyle choices. Correlation does not establish causation, and this data cannot tell us whether metformin caused better outcomes or whether better-health-engaged patients happened to take metformin.
Animal Studies
Metformin has extended lifespan in multiple animal models, including C. elegans, mice, and rats. Animal longevity data provides mechanistic plausibility but doesn’t reliably predict human outcomes — decades of anti-ageing research have repeatedly failed to translate animal lifespan data to human benefit.
Small Human Trials
A small number of randomised trials in healthy older adults have examined specific metformin outcomes with mixed results. A significant study by Konopka et al. (2019) found metformin blunted some of the physical fitness and muscle-building benefits of aerobic exercise training in older adults — a concerning finding for active individuals considering off-label use.
Metformin in Australia: Prescription and PBS
In Australia, metformin is listed on the Pharmaceutical Benefits Scheme (PBS) for type 2 diabetes — making it one of the most affordable prescription medicines available. For PBS-eligible patients with diabetes, a standard patient co-payment applies.
For healthy adults without diabetes, accessing metformin requires:
- An off-label prescription (at the GP’s discretion and clinical judgement)
- The cost is not PBS-subsidised for off-label use
- This is not standard practice in Australia and sits outside current clinical guidelines
No Australian clinical guideline currently recommends metformin for anti-ageing purposes in healthy adults. Off-label prescribing is legal but represents the GP accepting clinical responsibility for use outside the approved indication. See our guide anti aging for men
Metformin vs Other Anti-Ageing Approaches
| Approach | Current Evidence Strength | Practicality | Notes |
| Daily SPF | ⭐⭐⭐⭐⭐ | Easy | Proven to prevent UV-driven collagen breakdown |
| Retinol/tretinoin (topical) | ⭐⭐⭐⭐⭐ | Accessible (retinol OTC) | Strongest topical anti-ageing evidence |
| Oral collagen peptides | ⭐⭐⭐⭐ | Available OTC | RCT evidence for skin outcomes |
| Exercise (resistance + aerobic) | ⭐⭐⭐⭐⭐ | Free | Strongest evidence for systemic healthy ageing |
| Mediterranean dietary pattern | ⭐⭐⭐⭐ | Diet change | Consistently associated with slower ageing markers |
| Metformin (off-label) | ⭐⭐⭐ | Prescription only | Promising observational data; RCT evidence pending |
| Rapamycin (off-label) | ⭐⭐ | Prescription only; more complex side effects | Further from clinical readiness for healthy adults |
| NAD+ precursors (NMN/NR) | ⭐⭐ | OTC available | Limited human trial data; mechanistically interesting |
The important context: Lifestyle factors — consistent exercise, non-smoking, Mediterranean dietary pattern, quality sleep, and daily SPF — have a stronger and more established evidence base for healthy ageing than metformin currently does for healthy individuals. Metformin doesn’t substitute for these.
The Exercise Interaction: An Important Consideration
The 2019 Konopka et al. study found that metformin partially blunted the skeletal muscle adaptations to aerobic exercise training in older healthy adults, including reduced mitochondrial biogenesis and diminished improvements in insulin sensitivity — benefits that exercise normally delivers. This finding has been replicated partially in subsequent studies.
Practical implication: For physically active people considering metformin off-label, this interaction is a meaningful consideration. The anti-ageing benefits of regular exercise are substantial and well-proven. A drug that blunts some of those benefits may not represent a net gain, even if metformin itself has independent anti-ageing mechanisms.
Metformin vs Rapamycin: What’s the Difference?
Both drugs are being investigated for longevity potential, but they differ significantly:
| Factor | Metformin | Rapamycin |
| Primary mechanism | AMPK activation | Direct mTOR inhibition |
| Ageing evidence | Strong observational; TAME trial ongoing | Strong animal data; very limited human trials |
| Safety profile | Extremely well-established (60+ years of use) | Immunosuppressive at clinical doses; more complex |
| Clinical readiness (healthy adults) | TAME trial will determine this post-2028 | Further from clinical readiness |
| Current off-label use | Some longevity clinics prescribe | Some biohackers use; not mainstream |
Neither drug is currently recommended for healthy adults in standard clinical practice in Australia.
Bryan Johnson’s Protocol: What It Actually Shows
Bryan Johnson’s highly publicised Blueprint protocol incorporates metformin among many other interventions — dietary, supplemental, and pharmacological. While generating significant media coverage, it represents an individual’s n=1 self-experimentation rather than clinical evidence. The confounding factors in any protocol involving dozens of simultaneous interventions make it impossible to isolate the contribution of any single component, including metformin.
It is worth noting: the longevity and biohacking community’s enthusiasm for metformin is significantly ahead of the clinical evidence base. and the same caution applies to many of the anti-aging supplements stacked alongside it in protocols like Blueprint. The TAME trial was specifically designed to resolve this gap — and its results will carry far more evidential weight than any individual’s self-reported outcomes.
Safety and Side Effects of Metformin
| Effect | Likelihood | Notes |
| Gastrointestinal (nausea, diarrhoea) | Common (10–30% initially) | Usually resolves within weeks; extended-release formulation reduces this |
| Vitamin B12 deficiency | Uncommon but documented | Requires monitoring with long-term use |
| Lactic acidosis | Very rare | Risk increases significantly with kidney impairment |
| Exercise benefit blunting | Documented in studies | Relevant for active individuals |
| Drug interactions | Check with GP | Interacts with some contrast dyes used in imaging |
Contraindications: Significant kidney disease (eGFR <30), liver disease, alcohol dependence, and certain contrast imaging procedures. Always disclose metformin use to any treating medical professional.
The Bottom Line for 2026
Metformin has genuinely intriguing preliminary evidence for anti-ageing potential, backed by a plausible mechanism and compelling observational data in diabetic populations. The TAME trial, which will provide the definitive answer for healthy older adults, is fully enrolled and ongoing — with results expected no earlier than 2028.
For people with type 2 diabetes already taking metformin for its approved indication, the existing data suggesting additional cardiovascular and potentially longevity benefits alongside blood glucose lowering is genuinely reassuring.
For healthy adults: the honest position in June 2026 is that the evidence to specifically recommend metformin for anti-ageing purposes in otherwise healthy people does not yet exist. The interventions with the strongest current evidence — regular exercise, non-smoking, daily SPF, appropriate topical actives like well-chosen anti-ageing ingredients, and collagen-supporting nutrition such as anti-ageing peptides — remain the foundation of evidence-based anti-ageing.
References
- Barzilai N, et al. Metformin as a tool to target ageing. Cell Metabolism. 2016;23(6):1060–1065.
- Campbell JM, et al. Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control. Ageing Research Reviews. 2017.
- TAME Trial. ClinicalTrials.gov NCT03451006. Albert Einstein College of Medicine / NIA. Status updated 2026.
- Konopka AR, et al. Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults. Aging Cell. 2019.
- Therapeutic Goods Administration. Metformin prescribing information. tga.gov.au. Accessed June 2026.
- Pharmaceutical Benefits Scheme. Metformin hydrochloride. pbs.gov.au. Accessed June 2026.
Last reviewed: July, 2026. Not medical advice. Metformin is a prescription medicine — speak with your GP before any use outside its approved indication.
